Immatics Announces Third Quarter 2026 Financial Results and Business UpdateGlobeNewswire Nov 10, 2026, 12:00:00 PM
Immatics Presents Clinical Activity of IMA402 PRAME Bispecific and IMA203CD8 PRAME Cell Therapy across Advanced Solid Tumors in Two Oral Presentations at 2026 ESMO Annual MeetingGlobeNewswire Oct 24, 2026, 6:30:00 AM